Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 5/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MBOAT4 | Q96T53 | 11/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4879793 | 0.91 | ENPP1 (0.52) | ENPP1HTTSMN1; SMN2MBOAT4GAA | |
| SCHEMBL5108626 | 0.80 | MBOAT4 (0.43) | MBOAT4 | |
| SCHEMBL5099089 | 0.79 | MBOAT4 (0.44) | MBOAT4 | |
| SCHEMBL174682 | 0.79 | GAA (0.45) | HTTSMN1; SMN2MBOAT4GAA | |
| SCHEMBL14081887 | 0.78 | ENPP1 (0.60) | ENPP1HTTSMN1; SMN2MBOAT4CYP3A4 | |
| SCHEMBL4694580 | 0.77 | ENPP1 (0.53) | ENPP1HTTSMN1; SMN2GAACYP3A4 | |
| SCHEMBL4879548 | 0.76 | ENPP1 (0.52) | ENPP1HTTSMN1; SMN2GAACYP3A4 | |
| SCHEMBL3133514 | 0.74 | MBOAT4 (0.43) | HTTSMN1; SMN2MBOAT4GAA | |
| SCHEMBL373945 | 0.73 | MBOAT4 (0.38) | MBOAT4 | |
| SCHEMBL22968380 | 0.72 | MBOAT4 (0.71) | ENPP1MBOAT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080188494-A1 | Use Of 5-Alkyl-6-Phenylalkyl-7-Aminoazolopyrimidines, Novel Azolopyrimidines, Processes For Their Preparation And Compositions Comprising Them | BASF AKTIENGESELLSCHAFT (DE) | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188494-A1 | Use Of 5-Alkyl-6-Phenylalkyl-7-Aminoazolopyrimidines, Novel Azolopyrimidines, Processes For Their Preparation And Compositions Comprising Them | RRM2, PNP, NT5C3B | ENPP1 818/4885HTT 2740/4885SMN1; SMN2 3970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.